RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
Phase 1/2 Terminated
5 enrolled 6 charts
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
22 enrolled 21 charts
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
Phase 1/2 Terminated
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Phase 1 Terminated
15 enrolled
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase 1/2 Terminated
21 enrolled 11 charts
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy
Terminated
98 enrolled
Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Phase 1/2 Terminated
5 enrolled 11 charts
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
Phase 1 Terminated
19 enrolled
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
Phase 1 Terminated
5 enrolled
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
Phase 1 Terminated
6 enrolled
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Phase 2 Terminated
1 enrolled 7 charts
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase 1/2 Terminated
24 enrolled 18 charts
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Phase 2 Terminated
2 enrolled 8 charts
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Phase 1 Terminated
12 enrolled
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Phase 2 Terminated
45 enrolled 15 charts
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
Phase 2 Terminated
34 enrolled 11 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Phase 1/2 Terminated
3 enrolled 14 charts
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Phase 1 Terminated
2 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Phase 2 Terminated
24 enrolled 13 charts
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
Terminated
241 enrolled
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
Phase 1 Terminated
26 enrolled
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Phase 1 Terminated
41 enrolled
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Terminated
6 enrolled 9 charts
Drosophila-generated CTL
Phase 2 Terminated
3 enrolled 8 charts
Dinaciclib in Treating Patients With Stage III-IV Melanoma
Phase 1/2 Terminated
12 enrolled 9 charts
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
Phase 2 Terminated
12 enrolled 10 charts
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
Phase 2 Terminated
1 enrolled 7 charts
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Phase 2 Terminated
10 enrolled 8 charts
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1/2 Terminated
46 enrolled 12 charts
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Terminated
18 enrolled 9 charts
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
Phase 2 Terminated
2 enrolled 7 charts
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Phase 2 Terminated
36 enrolled 14 charts
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Phase 1/2 Terminated
34 enrolled 20 charts
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
Phase 2 Terminated
3 enrolled 10 charts
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Phase 2 Terminated
4 enrolled 9 charts
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
Phase 2 Terminated
3 enrolled 8 charts
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
Phase 2 Terminated
50 enrolled 13 charts
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Phase 2 Terminated
9 enrolled 9 charts
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Phase 1/2 Terminated
9 enrolled 13 charts
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
Phase 2 Terminated
5 enrolled 9 charts
A Phase II Study of UCN-01 in Metastatic Melanoma
Phase 2 Terminated
17 enrolled 6 charts
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
Phase 1/2 Terminated
3 enrolled 8 charts
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Phase 1 Terminated
5 enrolled
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
Phase 2 Terminated
2 enrolled 9 charts
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 2 Terminated
28 enrolled
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
Phase 2 Terminated
4 enrolled 7 charts
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Phase 1 Terminated
22 enrolled
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Phase 1 Terminated
40 enrolled
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
Phase NA Terminated
30 enrolled